Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes

Gastroenterology

Volumn 138, Issue 1, 2010, Pages 52-64

  Salem, Riad ^a   Lewandowski, Robert J ^a   Mulcahy, Mary F ^a   Riaz, Ahsun ^a   Ryu, Robert K ^a   Ibrahim, Saad ^a   Atassi, Bassel ^a   Baker, Talia ^a   Gates, Vanessa ^a   Miller, Frank H ^a   Sato, Kent T ^a   Wang, Ed ^a   Gupta, Ramona ^a   Benson, Al B ^a   Newman, Steven B ^a   Omary, Reed A ^a   Abecassis, Michael ^a   Kulik, Laura ^b  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; MICROSPHERE; YTTRIUM 90;

ABDOMINAL PAIN; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANOREXIA; ARTICLE; ARTIFICIAL EMBOLISM; BILIRUBIN BLOOD LEVEL; BRACHYTHERAPY; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; DIARRHEA; FATIGUE; FEMALE; FEVER; HUMAN; LIVER CELL CARCINOMA; LONGITUDINAL STUDY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIOEMBOLIZATION; SIDE EFFECT; SURVIVAL TIME; TREATMENT OUTCOME; ULCER; VOMITING; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

EID: 72249087123     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.09.006     Document Type: Article

References (46)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Bosch F.X., Ribes J., Diaz M., et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (2004) S5-S16
3. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
4. Kulik L.M., Atassi B., van Holsbeeck L., et al. Yttrium-90 microspheres (TheraSphere(R)) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94 (2006) 572-586
5. Lu D.S., Yu N.C., Raman S.S., et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 234 (2005) 954-960
6. Maddala Y.K., Stadheim L., Andrews J.C., et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 10 (2004) 449-455
7. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
8. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
9. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009) 25-34
10. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
11. Ingold J.A., Reed G.B., Kaplan H.S., et al. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 93 (1965) 200-208
12. Dawson L.A., McGinn C.J., and Lawrence T.S. Conformal chemoradiation for primary and metastatic liver malignancies. Semin Surg Oncol 21 (2003) 249-255
13. Kennedy A.S., Nutting C., Coldwell D., et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60 (2004) 1552-1563
14. Sato K., Lewandowski R.J., Bui J.T., et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere(R)): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 29 (2006) 522-529
15. Sala M., Llovet J.M., Vilana R., et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 40 (2004) 1352-1360
16. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 35 (2001) 421-430
17. Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100 (2008) 698-711
18. Llovet J.M., Fuster J., and Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10 (2004) S115-S120
19. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
20. Katyal S., Oliver III J.H., Peterson M.S., et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology 216 (2000) 698-703
21. Leung T.W., Lau W.Y., Ho S.K., et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33 (1995) 919-924
22. TheraSphere Yttrium-90 microspheres. [package insert] (2004), MDS Nordion, Kanata, Canada
23. Salem R., and Thurston K.G. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations. J Vasc Interv Radiol 17 (2006) 1251-1278
24. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
25. Takayasu K., Arii S., Ikai I., et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131 (2006) 461-469
26. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
27. Geschwind J.F., Salem R., Carr B.I., et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127 (2004) S194-S205
28. Goin J.E., Salem R., Carr B.I., et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 16 (2005) 205-213
29. Goin J.E., Salem R., Carr B.I., et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol 16 (2005) 195-203
30. Murthy R., Brown D.B., Salem R., et al. Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. J Vasc Interv Radiol 18 (2007) 553-561 quiz 562
31. Rhee T.K., Naik N.K., Deng J., et al. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 19 (2008) 1180-1186
32. Salem R., Lewandowski R.J., Atassi B., et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16 (2005) 1627-1639
33. Thomas M.B., O'Beirne J.P., Furuse J., et al. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 15 (2008) 1008-1014
34. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 4293-4300
35. Keppke A.L., Salem R., Reddy D., et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR Am J Roentgenol 188 (2007) 768-775
36. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
37. Yao F.Y., Hirose R., LaBerge J.M., et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 11 (2005) 1505-1514
38. Moylan C.A., Brady C.W., Johnson J.L., et al. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 300 (2008) 2371-2378
39. Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol 48 (2008) 380-381
40. Calvet X., Bruix J., Gines P., et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology 12 (1990) 753-760
41. Giannini E., Romagnoli P., Fasoli A., et al. Influence of age on clinical presentation, therapeutic options, and prognosis in anti-HCV positive cirrhotic patients with hepatocellular carcinoma. Age Ageing 31 (2002) 457-462
42. Lok A.S., Seeff L.B., Morgan T.R., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136 (2009) 138-148
43. Arii S., Yamaoka Y., Futagawa S., et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 32 (2000) 1224-1229
44. Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360 (2009) 563-572
45. Hecht J.R., Mitchell E., Chidiac T., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27 (2009) 672-680
46. Riaz A., Kulik L., Lewandowski R.J., et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49 (2009) 1185-1193